Biodonostia Research Institute, San Sebastián, Spain.
Blood Rev. 2013 May;27(3):143-54. doi: 10.1016/j.blre.2013.04.002. Epub 2013 Apr 25.
MicroRNAs (miRNAs) have become one of the hottest topics in biology over recent years, but remarkably have only been formally recognized for just over 10 years. These endogenously produced short (19-24 nt) non-coding RNAs have introduced an entirely new paradigm in our understanding of gene control and it is now evident that miRNAs play a crucial regulatory role in many, if not all, physiological and pathological processes. In this review we provide an overview of the role and potential clinical utility for miRNAs in hematological malignancies and their function in normal hematopoiesis. Although still in its infancy, the miRNA field has already added much to our understanding of hematological processes, and provides us with novel tools as both biomarkers and therapeutic agents for hematological malignancies.
MicroRNAs (miRNAs) 近年来已成为生物学领域最热门的话题之一，但令人惊讶的是，它们仅在过去 10 多年才得到正式认可。这些内源性产生的短（19-24nt）非编码 RNA 在我们对基因调控的理解中引入了一个全新的范例，现在很明显，miRNAs 在许多生理和病理过程中都发挥着至关重要的调节作用，如果不是全部的话。在这篇综述中，我们概述了 miRNAs 在血液系统恶性肿瘤中的作用和潜在临床应用及其在正常造血中的功能。尽管 miRNA 领域仍处于起步阶段，但它已经极大地加深了我们对血液学过程的理解，并为我们提供了新的工具，作为血液系统恶性肿瘤的生物标志物和治疗剂。
